



Increased Expression of lncRNA UCA1 and HULC Is Required for Pro-inflammatory Response During LPS Induced Sepsis in Endothelial Cells

Ying Chen, Yao Fu, Yan-fei Song and Nan Li*

Department of Intensive Care Unit, The First Hospital of Jilin University, Changchun, China

OPEN ACCESS

Edited by:

Brian James Morris,
The University of Sydney, Australia

Reviewed by:

Gautham Yepuri,
New York University, United States
Michelino Di Rosa,
Università degli Studi di Catania, Italy

*Correspondence:

Nan Li
leenan_med@163.com

Specialty section:

This article was submitted to
Integrative Physiology,
a section of the journal
Frontiers in Physiology

Received: 08 January 2019

Accepted: 29 April 2019

Published: 21 May 2019

Citation:

Chen Y, Fu Y, Song Y-f and Li N
(2019) Increased Expression
of lncRNA UCA1 and HULC Is
Required for Pro-inflammatory
Response During LPS Induced Sepsis
in Endothelial Cells.
Front. Physiol. 10:608.
doi: 10.3389/fphys.2019.00608

Systemic uncontrolled inflammatory response, also termed as sepsis, is responsible for many mortalities. Bacterial endotoxin, lipopolysaccharide (LPS), is a major cause of sepsis in endothelial cells. Even though a lot of research has been done to define underlying mechanisms of LPS induced sepsis, the role of long non-coding RNAs (lncRNAs), a group of >200 kb RNAs in sepsis is not well-defined. Expression of pro-inflammatory mediators *IL6*, *ICAM1*, and *VCAM1* (which encodes interleukin-6, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, respectively) were determined following LPS treatment of human dermal microvascular endothelial cells (HMECs) for 24 h to confirm sepsis induction. RNA immunoprecipitation (RIP) analysis was performed using the chromatin modifying proteins (CMPs), heterogeneous nuclear ribonucleoprotein (hnRNP) K and corepressors of the RE-1 silencing transcription factor (coREST) as individual baits. Quantitative real time polymerase chain reaction (qRT-PCR) was performed on RNA isolated from immunoprecipitated pellets for six different lncRNAs. The effect of the differentially expressed lncRNAs were determined by ectopic overexpression of the lncRNAs before induction of sepsis. Expression of *IL6*, *ICAM1*, and *VCAM1* were significantly upregulated following treatment of the HMECs with LPS for 24 h confirming induction of sepsis. RIP and qRT-PCR analysis revealed that the lncRNAs HULC, UCA1, and MALAT-1 were significantly enriched with the CMPs after sepsis. RNA interference using siRNAs targeting HULC and UCA1, but not MALAT-1, decreased the expression of *IL6*, *ICAM1*, and *VCAM1* to endogenous levels. Our results were further validated in an *in vivo* model of sub-lethal LPS-induced sepsis, whereby siRNA mediated knockdown of UCA1 and HULC lncRNAs prevented induction of *VCAM1*, *ICAM1*, and *IL6*, as assayed by immunohistochemistry. Cumulatively, these results suggest that LPS induced *in vitro* sepsis in endothelial cells and induction of pre-inflammatory mediators are at least in part due to increased expression of the UCA1 and HULC lncRNAs.

Keywords: long non-coding RNA, lncRNA, HULC, UCA1, MALAT-1, sepsis, LPS, endothelial cells

INTRODUCTION

Sepsis is an uncontrolled systemic inflammatory response that can affect multiple organs in the body and is a major cause of worldwide mortality (Dauphinee and Karsan, 2006; Vincent et al., 2011; Randolph and McCulloh, 2014). When lipopolysaccharide (LPS), present within the cell wall of Gram-negative bacteria, encounters endothelial cells, a signaling cascade is induced resulting in sepsis (Dauphinee and Karsan, 2006) in initiated.

Endothelial cells line the microcirculatory route, maintaining an antithrombotic surface and in turn regulating vasomotor tonicity and normal blood flow (Danese et al., 2007; Chelazzi et al., 2015). Exposure of the microvascular endothelium to inflammatory cytokines or to endotoxins like LPS result in induced expression of pro-inflammatory markers inclusive of interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) (Danese et al., 2007; Chelazzi et al., 2015).

It is well documented that abnormal expression of both small (<200 kb) and long (lncRNA; >200 kb) non-coding RNAs (ncRNAs) is associated with different human diseases (Bussemakers et al., 1999; Srikantan et al., 2000; Iacoangeli et al., 2004; Petrovics et al., 2004; Gupta et al., 2010). In fact, lncRNA expression also seems to be involved in normal development processes as is evidenced by impaired neuronal development by knockdown of either *Pantr2* (*linc-Brn1b*) or *Evf2* (Bond et al., 2009; Sauvageau et al., 2013). Given the central role of LPS in mediating sepsis and septic shock it is not surprising that the mechanisms regulating the pathophysiology of sepsis has been studied in detail (Beck et al., 2006; Singh et al., 2016; Yu et al., 2017).

However, beyond a few studies (Singh et al., 2016; Chowdhury et al., 2017), including one which showed that the lncRNAs EGO (NONHSAT087634) and HOTAIRM1 (NONHSAT119666) are alternatively spliced and that expression of lnc-IL7R is increased during LPS induced sepsis (Chowdhury et al., 2017), not much is known about how altered lncRNA expression is related to pathophysiology of sepsis. HULC (highly upregulated in liver cancer) is a 16 kb lncRNA at chromosomal location 6p24.3 and is has been shown to be overexpressed in patients with liver cancer (Ruan et al., 2018). LncRNA urothelial carcinoma-associated 1 (UCA1) at chromosomal location 19p13.12 was initially identified in human bladder carcinoma but plays widespread role in inflammation and tumorigenesis (Liu et al., 2019). It has been shown to regulate Hippo signaling pathway as well as miRNA sponge function of miR-96 and miR-135a (Liu et al., 2019). Hence, our goal was to identify putative role of lncRNA in LPS-induced sepsis.

The lncRNAs directly interact with chromatin modifying proteins (CMPs) – heterogeneous nuclear ribonucleoprotein K (hnRNP K), corepressors of the RE-1 silencing transcription factor (coREST), polycomb

repressor complex 2, and Sin3A. This interaction results in lncRNA-mediated changes in lineage specific gene expression and epigenetic silencing (Nagano et al., 2008; Huarte et al., 2010; Nagano and Fraser, 2011; Pandey and Kanduri, 2011). Therefore, RNA immunoprecipitation (RIP) analysis using CMP proteins as bait affords a way of elucidating lncRNA involved in a particular physiological context. Using hnRNP K and coREST as the baits, RIP analysis revealed that expression of three lncRNAs, whose expression is significantly upregulated during LPS-induced sepsis in endothelial cells *in vitro*, mediates the inflammatory response.

MATERIALS AND METHODS

Cell Culture and LPS Treatment

Human dermal microvascular endothelial cells (HMECs; Lonza, Basel, Switzerland) were cultured as described previously (Rydikina et al., 2010). Briefly, cells were cultured in MCDB 131 medium (Caisson's Laboratories) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific, Shanghai, China), 10 ng/ml epidermal growth factor (Thermo Fisher Scientific), 1 µg/ml hydrocortisone (Sigma-Aldrich, Shanghai, China), and 10 mM L-Glutamine (Thermo Fisher Scientific). LPS from *Escherichia coli* (*E. coli* O111: B4; Invivogen, San Diego, CA, United States) was resuspended in distilled water just before use. HMECs were treated with 1 µg/ml LPS for 24 h.

RNA Immunoprecipitation

After 24 h, untreated and LPS treated HMECs were washed twice with ice-cold PBS and then lysed in buffer containing 1.28 M sucrose, 40 mM Tris-HCl (pH 7.5), 20 mM MgCl₂, and 4% (v/v) Triton X-100. Followed by centrifugation at 2700 × g for 10 min. The nuclear pellet was resuspended in RIP buffer (Thermo Fisher Scientific). The hnRNP K antibody (EP943Y clone, ab52600; Abcam, Waltham, MA, United States) and coREST antibody (polyclonal ChIP grade; 07-455; Millipore, United States) was used to perform immunoprecipitation using magnetic agarose A/G beads (Thermo Fisher Scientific) following manufacturer's protocol. Control RIP using IgG was performed. Immunoprecipitates were washed thrice with RIP buffer before being processed as described in the next section.

RNA Isolation From Immunoprecipitates and qRT-PCR

RNA from the immunoprecipitated pellets or from total cell lysates were isolated using the RNeasy kit (Qiagen, Grand Island, NY, United States). The KAPA SYBR® FAST One-Step qRT-PCR Kit (KAPA Biosystems, Wilmington, MA, United States) was used using 1 µg of RNA as input. Primers used for amplification were:

<i>ICAM1</i>	Forward – 5′ - GGCCTCAGTCAGTGTGA -3′ Reverse – 5′ - AACCCCATTCAGCGTCA -3′
<i>VCAM1</i>	Forward – 5′ - CCGGATTGCTGCTCAGATT GGA -3′ Reverse – 5′ - AGCGTGGAATTGGTCCCC TCA -3′
<i>IL6</i>	Forward – 5′ - GGTACATCCTCGACGGCA TCT -3′ Reverse – 5′ - GTGCCTCTTTGCTGCTTTC AC -3′
<i>GAPDH</i>	Forward – 5′ - GCCAAAAGGGTCATCATC TC -3′ Reverse – 5′ - GGCCATCCACAGTCTTCT -3′
<i>HOTAIR</i>	Forward - 5′ - CAGTGGGAACTCTGACTCG -3′ Reverse – 5′ - GTGCCTGGTGTCTCTTACC -3′
<i>HULC</i>	Forward – 5′ - TCATGATGGAATTGGAGCCTT -3′ Reverse – 5′ - CTCTTCCTGGCTTGCAGATTG -3′
<i>MEG3</i>	Forward – 5′ - GCCAAGCTTCTTCAAAGGCC -3′ Reverse – 5′ - TTCCACGGAGTAGAGCGAGTC -3′
<i>NEAT1</i>	Forward – 5′ - TGGCTAGCTCAGGGCTTCAG -3′ Reverse – 5′ - TCTCTTGCCAAGCTTCTTTC -3′
<i>UCA1</i>	Forward – 5′ - CATGCTTGACACTTGGTGCC -3′ Reverse – 5′ - GGTCGCAGGTGGATCTCTTC -3′
<i>MALAT-1</i>	Forward – 5′ - TAGGAAGACAGCAGCAGACA GG -3′ Reverse – 5′ - TTGCTCGCTTGCTCCTCAGT -3′

ICAM1, *VCAM1*, and *IL6* expression levels were calculated by the 2- $\Delta\Delta$ Ct method. *GAPDH* was used as an endogenous control for data normalization. The data was also re-analyzed with 18s rRNA and did not show any difference as when *GAPDH* was used (data not shown). Relative enrichment of lncRNAs in RIP analysis was performed based on normalization to enrichment with just IgG.

RNA Interference

The following siRNAs from Thermo Fisher Scientific were used against *MALAT-1* – assay IDs n272231 and n272232; *HULC* – assay IDs n272667 and n272668; and *UCA1* – assay IDs n272525 and n272526. HMECs were transiently transfected with both siRNAs targeting each lncRNA at the same time using Lipofectamine LTX (Thermo Fisher Scientific; 100 nM final concentration). Seventy-two hours post-transfection, cells were either left untreated or treated with 1 μ g/ml LPS for 24 h before cells were harvested. Successful knockdown was verified by qRT-PCR.

Animal Studies

Eleven-week C57BL/6 mice were intraperitoneally injected with a sub-lethal dose of LPS (1 mg/kg body mass). Control scramble siRNA or siRNA targeting *HULC* and *UCA1* (13 μ g/week in 100 μ l volume) were administered by tail-vein injection, using equal volume mixtures of Lipofectamine™ 2000. Two weeks later, mice were euthanized by CO₂ narcosis. The aortic were carefully excised and fixed with 10% formalin solution.

Paraffin sections (5 μ m thickness) of aorta were prepared for immunohistochemistry (IHC) staining using anti-*ICAM1* antibody (clone 1A29, Thermo Fisher Scientific), anti-*VCAM1* (clone 429, Thermo Fisher Scientific), and anti-*IL6* antibody (ab6672, Abcam). Images were scored based on percent staining by a pathologist blinded to the identity of the tissue specimens.

Statistical Analysis

Data is represented as mean \pm standard deviation (SD). Statistical significance was determined by the two-tailed Student's *t*-test. A *P* < 0.05 was considered as statistically significant.

RESULTS

Human dermal microvascular endothelial cells were treated with LPS for 24 h and then RNA isolated from untreated and LPS treated HMECs were assayed for relative expression of the pro-inflammatory mediators, *ICAM1*, *VCAM1*, and *IL6*. LPS treatment significantly induced *ICAM1* (14.2 \pm 0.57 in LPS vs. 2 \pm 1.9 in untreated), *VCAM1* (9.3 \pm 0.87 in LPS vs. 2.1 \pm 1.09 in untreated), and *IL6* (10.1 \pm 0.61 in LPS vs. 1.9 \pm 0.9 in untreated; *P* < 0.05 in each case; **Figure 1**), confirming successful induction of *in vitro* sepsis.

RNA immunoprecipitation was performed using anti-hnRNP K, anti-coREST, and the corresponding IgG antibodies from lysates obtained from untreated and LPS treated HMEC cells. Immunoprecipitation in each case was confirmed by immunoblotting (**Figure 2A**). Relative enrichment, compared to IgG, for *HOTAIR*, *HULC*, *MEG3*, *NEAT1*, *UCA1*, and *MALAT-1*






FIGURE 1 | Transcription of *IL6*, *ICAM1*, and *VCAM1* encoding interleukin-6, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, respectively, were upregulated during LPS induced sepsis. Expression of *ICAM1*, *VCAM1*, and *IL6* mRNAs were determined by qRT-PCR in untreated or LPS-treated HMECs. Data represent mean \pm standard deviation of three independent experiments, post-normalization to *GAPDH* expression. **P* < 0.05, compared to untreated cells.




lncRNAs were determined in hnRNP K (Figure 2B) and co-REST (Figure 2C) immunoprecipitates-derived RNA. HULC, UCA1, and MALAT-1 were significantly enriched in both RIP profiles ($P < 0.05$ in each case compared to RIP from lysates obtained from untreated cells). There was no significant difference in enrichment obtained in the LPS treated lysates with hnRNP K or coREST antibodies, indicating equivalent affinity for the lncRNAs for the CMP components.

We next wanted to determine if there was a correlation between induction of the proinflammatory markers and increase in lncRNA enrichment in the CMP complex, we transiently transfected the HMECs with either a control scramble siRNA or two independent siRNAs targeting either MALAT-1, UCA1, or HULC. Seventy-two hours post-transfection, the HMECs were either left untreated or treated with LPS for an additional 24 h. Quantitative RT-PCR was performed to confirm successful silencing of the lncRNA expression by the respective siRNAs. Compared to the control scramble siRNA, the siRNAs specific to MALAT-1, UCA1, or HULC, respectively, significantly down regulated the expression of MALAT-1, UCA1, and HULC in LPS-treated HMECs (Figure 3).


Silencing of MALAT-1 did not result in significant decrease in expression of *ICAM1*, *VCAM1*, and *IL6* in the LPS treated HMECs (*ICAM1* 14.2 ± 1.9 folds in LPS group vs. 14.3 ± 0.58 in LPS + si-MALAT-1 group, $P > 0.05$; *VCAM1*: 9.3 ± 1.09 folds in LPS group vs. 9.1 ± 0.41 in LPS + si-MALAT-1 group,






$P > 0.05$; and, *IL6*: 10.1 ± 0.9 folds in LPS group vs. 11.2 ± 0.31 in LPS + si-MALAT-1 group, $P > 0.05$) (Figure 4A). Silencing of UCA1 significantly decreased the expression of *ICAM1*, *VCAM1*, and *IL6* in the LPS treated HMECs to those observed in the endogenous untreated HMECs (*ICAM1* 14.2 ± 1.9 folds in LPS group vs. 1.9 ± 0.98 in LPS + si-UCA1 group, $P < 0.05$; *VCAM1*: 9.3 ± 1.09 folds in LPS group vs. 2.31 ± 0.83 in LPS + si-UCA1 group, $P < 0.05$; and, *IL6*: 10.1 ± 0.9 folds in LPS group vs. 1.75 ± 0.83 in LPS + si-UCA1 group, $P < 0.05$) (Figures 4B, 5). Silencing of HULC lncRNA also had a similar effect to silencing of UCA1 lncRNA. Silencing of HULC significantly decreased

the expression of *ICAM1*, *VCAM1*, and *IL6* in the LPS treated HMECs to those observed in the endogenous untreated HMECs (*ICAM1* 14.2 ± 1.9 folds in LPS group vs. 2.1 ± 0.04 in LPS + si-HULC group, $P < 0.05$; *VCAM1*: 9.3 ± 1.09 folds in LPS group vs. 2.3 ± 0.02 in LPS + si-HULC group, $P < 0.05$; and, *IL6*: 10.1 ± 0.9 folds in LPS group vs. 1.86 ± 0.07 in LPS + si-HULC group, $P < 0.05$) (Figures 4C, 6). Taken together, these results indicate that increase in proinflammatory *ICAM1*, *VCAM1*, and *IL6* in HMECs during LPS induced sepsis *in vitro* is at least in part due to increase in expression of the lncRNAs HULC and UCA1.





DISCUSSION

It has been shown comprehensively that lncRNAs regulate gene expression during development, normal physiological processes and in aberrant disease contexts (Perez et al., 2008; Guttman et al., 2011). Even though lncRNAs do not encode protein products changes in their levels of expression seem to regulate expression of messenger RNA targets in these scenarios.

The results from the current study show that along with lnc-IL17R (Chowdhury et al., 2017), lncRNAs MALAT-1, HULC, and UCA1 are also upregulated during LPS induced sepsis. Among the upregulated lncRNAs, HULC and UCA1 seem to regulate induction in expression of the messenger RNAs for the proinflammatory interleukin-6 (IL-6), intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1). Given our *in vivo* results it seems that targeted knockdown of HULC and UCA1 might be a viable therapeutic option for sepsis, even though long-term stability and directed organ-specific delivery will be potential problems.

It remains to be determined how, if at all, upregulation of MALAT-1 impinges on LPS induced sepsis. It is highly possible that there are other targets whose expression is also modulated following induction in expression of the HULC, UCA1, and MALAT-1 lncRNAs during sepsis in endothelial cells. This becomes even more important because it has been shown that MALAT-1 actually mediates inflammation in traumatic brain injury. It also remains to be determined if the identity of the lncRNAs and their gene targets remain same across different forms of sepsis, and during LPS induced sepsis *in vivo*. The CRNDE lncRNA has been shown to trigger inflammation

through the TLR3-NF- κ B cytokine signaling pathway. Whether CRNDE is involved in sepsis remains to be determined.

The current study does suffer from some technical limitations. Foremost is RIP was performed using two of the four components of the CMP complex. Whether similar enrichment of lncRNAs are observed when RIP is performed using Sin3A and polycomb repressor complex 2 is imperative to determine as affinity of the lncRNAs might not be the same for all four components of the CMP. Additionally, it remains to be determined if other lncRNAs are also involved in the pathogenesis of sepsis.

In addition, RNAseq or lncRNA microarray should be performed on the RIP immunoprecipitates to identify the entire cohort of differentially enriched lncRNAs. Finally, we evaluated lncRNA enrichment in the CMP complex at one dose and one time point post-LPS treatment. It remains to be determined if the lncRNAs' enrichment within the CMP complex is time and dose dependent following treatment with LPS.

ETHICS STATEMENT

The study was approved by IACUC of The First Hospital of Jilin University.

AUTHOR CONTRIBUTIONS

NL designed the experiments. YC, YF, and Y-fS performed the experiments and analyzed the data. YC and NL prepared the manuscript. All authors have read the manuscript.

REFERENCES

- Beck, G. C., Rafat, N., Brinkkoetter, P., Hanusch, C., Schulte, J., Haak, M., et al. (2006). Heterogeneity in lipopolysaccharide responsiveness of endothelial cells identified by gene expression profiling: role of transcription factors. *Clin. Exp. Immunol.* 143, 523–533.
- Bond, A. M., Vangompel, M. J., Sametsky, E. A., Clark, M. F., Savage, J. C., Disterhoft, J. F., et al. (2009). Balanced gene regulation by an embryonic brain ncRNA is critical for adult hippocampal GABA circuitry. *Nat. Neurosci.* 12, 1020–1027. doi: 10.1038/nn.2371
- Bussemakers, M. J., Van Bokhoven, A., Verhaegh, G. W., Smit, F. P., Karthaus, H. F., Schalken, J. A., et al. (1999). DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. *Cancer Res.* 59, 5975–5979.
- Chelazzi, C., Villa, G., Mancinelli, P., De Gaudio, A. R., and Adembi, C. (2015). Glycocalyx and sepsis-induced alterations in vascular permeability. *Crit. Care* 19:26. doi: 10.1186/s13054-015-0741-z
- Chowdhury, I. H., Narra, H. P., Sahni, A., and Khanipov, K. (2017). Expression profiling of long noncoding RNA splice variants in human microvascular endothelial cells: lipopolysaccharide effects in vitro. *Mediat. Inflamm.* 2017:3427461. doi: 10.1155/2017/3427461
- Danese, S., Dejana, E., and Fiocchi, C. (2007). Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. *J. Immunol.* 178, 6017–6022.
- Dauphinee, S. M., and Karsan, A. (2006). Lipopolysaccharide signaling in endothelial cells. *Lab. Invest.* 86, 9–22.
- Gupta, R. A., Shah, N., Wang, K. C., Kim, J., Horlings, H. M., Wong, D. J., et al. (2010). Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. *Nature* 464, 1071–1076. doi: 10.1038/nature08975
- Guttman, M., Donaghey, J., Carey, B. W., Garber, M., Grenier, J. K., Munson, G., et al. (2011). lincRNAs act in the circuitry controlling pluripotency and differentiation. *Nature* 477, 295–300. doi: 10.1038/nature10398
- Huarte, M., Guttman, M., Feldser, D., Garber, M., Koziol, M. J., Kenzelmann-Broz, D., et al. (2010). A large intergenic noncoding RNA induced by p53 mediates global gene repression in the p53 response. *Cell* 142, 409–419. doi: 10.1016/j.cell.2010.06.040
- Iacoangeli, A., Lin, Y., Morley, E. J., Muslimov, I. A., Bianchi, R., Reilly, J., et al. (2004). BC200 RNA in invasive and preinvasive breast cancer. *Carcinogenesis* 25, 2125–2133.
- Liu, Y., Feng, W., Gu, S., Wang, H., Zhang, Y., Chen, W., et al. (2019). The UCA1/KRAS axis promotes human pancreatic ductal adenocarcinoma stem cell properties and tumor growth. *Am. J. Cancer Res.* 9, 496–510.
- Nagano, T., and Fraser, P. (2011). No-nonsense functions for long noncoding RNAs. *Cell* 145, 178–181. doi: 10.1016/j.cell.2011.03.014
- Nagano, T., Mitchell, J. A., Sanz, L. A., Pauler, F. M., Ferguson-Smith, A. C., Feil, R., et al. (2008). The Air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. *Science* 322, 1717–1720. doi: 10.1126/science.1163802
- Pandey, R. R., and Kanduri, C. (2011). Transcriptional and posttranscriptional programming by long noncoding RNAs. *Prog. Mol. Subcell. Biol.* 51, 1–27. doi: 10.1007/978-3-642-16502-3_1
- Perez, D. S., Hoage, T. R., Pritchett, J. R., Ducharme-Smith, A. L., Halling, M. L., Ganapathiraju, S. C., et al. (2008). Long, abundantly expressed non-coding transcripts are altered in cancer. *Hum. Mol. Genet.* 17, 642–655.
- Petrovics, G., Zhang, W., Makarem, M., Street, J. P., Connelly, R., Sun, L., et al. (2004). Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. *Oncogene* 23, 605–611.
- Randolph, A. G., and McCulloh, R. J. (2014). Pediatric sepsis: important considerations for diagnosing and managing severe infections in infants, children, and adolescents. *Virulence* 5, 179–189. doi: 10.4161/viru.27045
- Ruan, L., Huang, L., Zhao, L., Wang, Q., Pan, X., Zhang, A., et al. (2018). The interaction of lincRNA-HEIH and lincRNA-HULC with HBXIP in hepatitis B patients. *Gastroenterol. Res. Pract.* 2018:9187316. doi: 10.1155/2018/9187316
- Rydkina, E., Turpin, L. C., and Sahni, S. K. (2010). *Rickettsia rickettsii* infection of human macrovascular and microvascular endothelial cells reveals activation of both common and cell type-specific host response mechanisms. *Infect. Immun.* 78, 2599–2606. doi: 10.1128/IAI.01335-09
- Sauvageau, M., Goff, L. A., Lodato, S., Bonev, B., Groff, A. F., Gerhardinger, C., et al. (2013). Multiple knockout mouse models reveal lincRNAs are required for life and brain development. *eLife* 2:e01749. doi: 10.7554/eLife.01749
- Singh, K. K., Matkar, P. N., Muhammad, S., Quan, A., Gupta, V., Teoh, H., et al. (2016). Investigation of novel LPS-induced differentially expressed long non-coding RNAs in endothelial cells. *Mol. Cell. Biochem.* 421, 157–168. doi: 10.1007/s11010-016-2797-8
- Srikantam, V., Zou, Z., Petrovics, G., Xu, L., Augustus, M., Davis, L., et al. (2000). PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. *Proc. Natl. Acad. Sci. U.S.A.* 97, 12216–12221.
- Vincent, J. L., Nelson, D. R., and Williams, M. D. (2011). Is worsening multiple organ failure the cause of death in patients with severe sepsis? *Crit. Care Med.* 39, 1050–1055. doi: 10.1097/CCM.0b013e31820eda29
- Yu, S., Chen, X., Xiu, M., He, F., Xing, J., Min, D., et al. (2017). The regulation of Jmjd3 upon the expression of NF-kappaB downstream inflammatory genes in LPS activated vascular endothelial cells. *Biochem. Biophys. Res. Commun.* 485, 62–68. doi: 10.1016/j.bbrc.2017.02.020

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Chen, Fu, Song and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.